Randomized, Single-blind, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD4076 Following Multiple Ascending Dose Administration to T2DM Subjects With Non-Alcoholic Fatty Liver Disease

Trial Profile

Randomized, Single-blind, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD4076 Following Multiple Ascending Dose Administration to T2DM Subjects With Non-Alcoholic Fatty Liver Disease

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 30 May 2017

At a glance

  • Drugs RG 125 (Primary)
  • Indications Non-alcoholic fatty liver disease
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors AstraZeneca
  • Most Recent Events

    • 23 Feb 2017 Status changed from recruiting to active, no longer recruiting.
    • 22 Dec 2016 Planned End Date changed from 1 Oct 2017 to 1 Dec 2017.
    • 22 Dec 2016 Planned primary completion date changed from 1 Oct 2017 to 1 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top